Lisen Imprinting Diagnostics

Name

Lisen Imprinting Diagnostics

Legal name

Lisen Imprinting Diagnostics (Wuxi) Co., Ltd.

Website

https://lisenid.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Molecular Cancer Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

Keywords

• Molecular diagnostics
• Cancer diagnostics
• Epigenetic biomarkers
• Laboratory developed tests
• Imprinting gene analysis

Headquarters

HQ city

Wilmington

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Molecular Diagnostic Testing Services: Laboratory-developed tests (LDTs) for cancer diagnosis. Currently the QCIGISH test for thyroid cancer is in market in China. Revenue generated from test processing fees charged to hospitals and clinical laboratories.
2. Technology Licensing: Licensing of proprietary QCIGISH technology and methodology to clinical laboratories and healthcare institutions globally, supported by granted patents in 17+ European countries
3. Drug Development Collaboration: Joint development of innovative drugs for lung cancer with Galixir using imprinted gene biomarkers combined with AI for small molecule drug design

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

LisenID develops and provides the QCIGISH molecular diagnostic platform for early cancer detection, leveraging Loss of Imprinting (LOI) biomarkers combined with AI-driven image analysis to produce objective risk assessment scores from routine biopsy samples. The company sells laboratory-developed tests (LDTs) and diagnostic testing services to hospitals and clinical laboratories, with the QCIGISH Thyroid Cancer Test currently commercialized in China and additional cancer-specific tests (lung, breast, skin, cervical, melanoma) in clinical validation or development.

Product overview

Lisen Imprinting Diagnostics offers the QCIGISH (Quantitative Chromogenic Imprinted Gene In-Situ Hybridization) platform as its core molecular diagnostic technology for early cancer detection. The platform detects Loss of Imprinting (LOI) biomarkers combined with AI-driven analysis to visually identify carcinogenesis. Currently, the QCIGISH Thyroid Cancer Test is in market in China. Additional cancer detection tests are in development or clinical validation, including lung cancer (in collaboration with Mayo Clinic), breast cancer, skin cancer, cervical cancer, and melanoma detection. The portfolio utilizes routine biopsy samples and provides objective, visual risk assessment scores.

Differentiator

Problem solved

Functional benefit

Products and services

• QCIGISH Thyroid Cancer Test QCIGISH-based diagnostic test for thyroid cancer detection using biopsy samples. Achieved 100% sensitivity and 100% specificity in a 550-patient validation study. Currently commercialized in China, targeting hospitals and clinical laboratories for early-stage thyroid nodule diagnosis, particularly cytologically indeterminate cases.
• QCIGISH Lung Cancer Test QCIGISH-based diagnostic test for lung cancer detection using TBNA, lavage, and biopsy samples. In development with Mayo Clinic collaboration. Clinical validation showed 99% sensitivity and 92% specificity for early-stage lung cancer and small pulmonary nodules.
• QCIGISH Breast Cancer Test QCIGISH-based diagnostic test for breast cancer detection using CNB (core needle biopsy) and FNA (fine needle aspiration) samples. In development as part of planned market entry.
• QCIGISH Skin Cancer Test QCIGISH-based diagnostic test for skin cancer detection using skin biopsy samples. In development with planned expansion into US and European markets.
• QCIGISH Cervical Cancer Test QCIGISH-based non-invasive early detection technology for cervical cancer risk stratification in HPV-positive individuals. Achieved 93.8% sensitivity and 83.6% specificity, validated in 259 clinical samples across multiple hospitals in collaboration with Sichuan University West China Second University Hospital.
• QCIGISH Melanoma Detection Early melanoma detection product under development in collaboration with Mayo Clinic. Designed to distinguish early in situ melanomas from benign moles to improve preoperative detection rates.

Quantifiable outcome

• Up to 95% accuracy in pre-clinical validation studies across 10,000+ cases
• +4 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Eight partnerships are on record, tiered core, supporting and minor.

• Mayo CliniccoreStrategic or Co-development Partner · 13 February 2025LisenID entered a know-how agreement with Mayo Clinic to research and develop innovative early cancer diagnostic solutions. Initial focus is on developing a QCIGISH-based laboratory-developed test (LDT) for early lung cancer detection using transbronchial needle aspiration (TBNA) samples for peripheral pulmonary lesions. Collaboration combines LisenID's epigenetic imprinting technology with Mayo Clinic's clinical expertise.
• Sichuan University West China Second University HospitalcoreStrategic or Co-development Partner · 11 October 2024Collaboration on cervical cancer detection research published in Cancer Communications (IF=20.1). Study validated QCIGISH technology for cervical cancer risk stratification in HPV-positive patients, analyzing 259 clinical samples from multiple hospitals including Chengdu Women and Children's Central Hospital, Zigong Maternal and Child Health Hospital, Chenghua District Maternal and Child Health Hospital, and Nanjing First Hospital.
• GalixircoreStrategic or Co-development Partner · 1 November 2020Joint development of innovative drugs for lung cancer combining Lisen Imprinting's epigenetic imprinting genes detection technology with Galixir's AI technology for small molecule drug design. Companies have identified a highly active drug candidate that could overcome drug resistance problems for SCLC and NSCLC patients. Multi-phase strategy combining technical expertise in biological research, pathogenesis, drug design, molecule optimization and cell detection.
• The Innovation SpacesupportingImplementation/ SI/ Consulting PartnerProvides residency and resources to LisenID in the form of lab space, resources, and as an incubator for growth in Delaware
• SBDC DelawaresupportingImplementation/ SI/ Consulting PartnerProvides business and commercialization support to LisenID
• Merck China Innovation CentersupportingGTM or Marketing PartnerLisen Imprinting participated in Merck China Innovation Center accelerator program (2019, 2nd session). Companies met through the accelerator and later established strategic collaboration on drug development with Galixir.
• Science Inc AcceleratorminorGTM or Marketing PartnerAccelerator program participant for growth and development support
• Creative Destruction LabminorGTM or Marketing PartnerAccelerator program participant for growth and development support

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/lisenid
• Xx.com/lisen_ID

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lisen Imprinting Diagnostics